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Which drugs should post-MI
patients routinely receive?
      patients should be placed on 
    the following medications 
          (TABLE): 
•   antiplatelet agents (strength of recom-
mendation [SOR]: A, meta-analysis 
for aspirin; A, multiple randomized 
controlled trials [RCTs] for aspirin plus 
clopidogrel)
•   a statin; atorvastatin has the best evi-
dence (SOR: B, a single RCT)
•  a beta-blocker (SOR: A, meta-analysis)
•   renin-angiotensin-aldosterone system 
blockers, whether or not the ejection 
fraction is diminished after myocardial 
infarction (MI) (SOR: A, meta-analysis 
for angiotensin-converting enzyme 
[ACE] inhibitor; B, single RCT for ACE 
inhibitor plus aldosterone blocker).
A
Evidence summary
A systematic review of 9 RCTs demonstrated 
that aspirin (75-325 mg) started soon after 
the onset of acute MI signifi cantly reduced 
mortality, reinfarction, and stroke at 1 month 
compared with placebo (absolute risk reduc-
tion [ARR]=3.8%; number needed to treat 
[NNT]=26; 95% confi dence interval [CI], 
23-30).1
One large RCT involving 17,187 patients 
with suspected acute MI showed that 162 mg 
aspirin given on the day of the MI resulted in 
a 2.6% ARR (NNT=38; 95% CI, 29-63) in vas-
cular deaths at 35 days compared with place-
bo.2 Th e survival benefi t persisted for as long 
as 10 years. Th e RCT also found no signifi -
cant diff erence between aspirin and placebo 
in rates of cerebral hemorrhage or bleeding 
requiring transfusions. 
Patients who have had an MI without ST 
segment elevation should take clopidogrel 
(75 mg/d) and aspirin (81 mg/d) for 12 months. 
Th e combination has been shown to result in 
a 2.1% ARR (NNT=48) in deaths, recurrent MI, 
and stroke compared with aspirin alone.3 Pa-
tients who have had an ST segment elevation 
MI should take clopidogrel in combination 
with aspirin for at least 2 weeks.4 
Intensive atorvastatin therapy 
lowers risk of death
Th e PROVE IT-TIMI 22 trial showed the ben-
efi t of early intensive therapy with the hy-
droxymethyl glutaryl coenzyme A reductase 
inhibitor atorvastatin to lower low-density 
lipoprotein <70 mg/dL post-MI.5 At 30 days af-
ter the event, atorvastatin 80 mg daily resulted 
in a 1.2% ARR in death and recurrent acute 
coronary syndrome (NNT=83; hazard ratio 
[HR]=0.72; 95% CI, 0.52-0.99). From 6 months 
to 24 months after the event, the ARR was 2.6% 
(NNT=38; HR=0.82; 95% CI, 0.69-0.99). 
Beta-blockers signifi cantly decrease 
late mortality
One systematic review of 63 RCTs showed 
that, in long-term trials, use of a beta-blocker 
signifi cantly reduced the late mortality rate 
(NNT=48; odds ratio [OR]=0.77; 95% CI, 0.70-
0.85).6 In another review of 82 RCTs, the mor-
tality rate between 6 months and 4 years after 
MI decreased markedly in patients receiving 
a beta-blocker (OR=0.77; 95% CI, 0.69-0.85).7 
ACE inhibitors decrease 
overall mortality, sudden cardiac death
An ACE inhibitor should be started regard-
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Patients who 
have had an 
MI without 
ST segment 
elevation should 
take clopidogrel 
and aspirin for 
12 months.
less of the ejection fraction or the presence or 
absence of left ventricular systolic dysfunc-
tion. One systematic review that compared 
long-term mortality rates of patients started 
on an ACE inhibitor within 14 days of acute 
MI versus placebo found that ACE inhibi-
tors signifi cantly decreased overall mortality 
and sudden cardiac deaths between 2 and 
42 months after the MI (NNT=42; OR=0.83; 
95% CI, 0.71-0.97).8 
Eplerenone + ACE inhibitor benefi t 
patients with post-MI heart failure
Th e selective aldosterone blocker eplerenone 
appears to benefi t patients with a decreased 
ejection fraction post-MI. Th e EPHESUS 
study demonstrated that eplerenone, when 
added to an ACE inhibitor, reduced all-cause 
mortality (ARR=1.4%; NNT=71; 95% CI, 
47-200; RR=0.69; 95% CI, 0.54-0.89) and sud-
den cardiac death (ARR=0.5%; NNT=200; 
95% CI, 125-∞; RR=0.63; 95% CI, 0.40-1.00) up 
to 30 days in patients with post-MI heart fail-
ure. Benefi ts were also seen after 16 months 
of treatment.9 
Recommendations 
Th e American College of Cardiology (ACC) and 
American Heart Association (AHA) provide the 
following recommendations in their joint 2006 
Guidelines for Secondary Prevention for Pa-
tients with Coronary and Other Atherosclerotic 
Vascular Disease:10
•   Low-dose aspirin should be used, as 
well as clopidogrel in combination 
with aspirin for up to 12 months after a 
non-ST elevation MI
•   ACE inhibitors or angiotensin recep-
tor blockers should be considered in all 
patients, and an aldosterone antago-
nist should be prescribed for patients 
with a diminished ejection fraction 
post-MI
•   Beta-blockers should be used in all post-
MI patients without contraindications. 
Th e ACC/AHA 2007 Guidelines for the 
Management of Patients with Unstable An-
gina/Non–ST-Elevation Myocardial Infarction 
recommend the same medication combina-
tions.11 So does the 2007 Focused Update of 
the ACC/AHA 2004 Guidelines for the Man-
Drug type Examples Precautions Contraindications
Antiplatelet agents Aspirin 81 mg/d;
clopidogrel 75 mg/d
Risk for bleeding;
use caution in 
patients taking 
warfarin
Active bleeding;
hypersensitivity 
RAAS blockers Lisinopril 20 mg/d;
losartan 50 mg/d;
eplerenone 50 mg/d
Hypotension, 
hyperkalemia, renal 
failure
Use eplerenone 
only with decreased 
ejection fraction
Hypersensitivity;
systolic blood 
pressure 
90 mm Hg
Beta-blockers Metoprolol 
100 mg bid
Hypotension, 
bradycardia, 
reactive airways
Systolic blood 
pressure 
90 mm Hg;
pulse rate 50 bpm
Statins Atorvastatin 
80 mg/d
Elevated AST/ALT, 
myositis
Active liver disease;
pregnancy/nursing 
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BPM, beats per minute; RAAS, renin-angiotensin-aldosterone 
system.
TABLE
Recommended drugs for post-MI patients
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Atorvastatin 
has been found 
to decrease the 
risk of death 
and recurrent 
acute coronary 
syndrome.
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agement of Patients with ST-Elevation Myo-
cardial Infarction, with the exception that 
clopidogrel in combination with aspirin is rec-
ommended for at least 14 days.12
Similarly, the British National Institute 
for Clinical Excellence Clinical Guideline 
48 recommends that all post-MI patients be 
off ered a combination of an ACE inhibitor, 
aspirin with clopidogrel, a beta-blocker, and 
a statin.13                JFP
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